FDA grants ZYN nicotine pouches modified risk tobacco status
Philip Morris International (PMI) has announced that the US Food and Drug Administration has issued Modified Risk Tobacco Product (MRTP) orders covering 20 variants of its ZYN nicotine pouch range. The decision, disclosed on 27 August 2026, marks the first time the FDA has granted MRTP status to any nicotine pouch product, and allows PMI's US business to make a specific reduced-risk claim on authorised ZYN products.
The permitted marketing statement reads: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." The FDA's granting order confirmed that, as actually used by consumers, the products would significantly reduce harm and the risk of tobacco-related disease to individual users while benefiting population health overall, accounting for both current tobacco users and non-users.
What the data showed
The FDA's review drew on consumer survey data submitted as part of PMI's modified risk tobacco product applications. Among adults who smoke and had begun using ZYN, more than half reported no cigarette consumption in the preceding 30 days. Of those who continued to smoke alongside ZYN use, 80.7% reduced their overall cigarette consumption, and 57.2% cut their daily cigarette count by more than half. ZYN pouches deliver nicotine via oral mucosal absorption, bypassing the combustion process that generates the bulk of harmful chemicals associated with cigarettes.
The company has not disclosed the full toxicological dataset submitted to the FDA, and long-term population-level data on dual use, product switching and nicotine dependence maintenance were not detailed in the release.
Regulatory and market context
The MRTP designation sits within a regulatory framework established under the Family Smoking Prevention and Tobacco Control Act, which requires applicants to demonstrate population-level benefit rather than individual risk reduction alone. The FDA has granted MRTP orders only sparingly: Swedish Match's General snus and versions of PMI's IQOS heated tobacco device were among the earliest recipients in their respective categories. Extending the designation to nicotine pouches broadens the set of smoke-free alternatives that can carry explicit reduced-risk messaging in US retail and advertising environments.
The nicotine pouch segment has grown rapidly in the United States, with ZYN commanding a dominant retail share. Competitors including British American Tobacco's Velo and several smaller brands are active in the space, though none holds comparable MRTP status at the time of writing. That regulatory asymmetry could prove commercially significant, giving PMI's US operation a compliant basis for differentiated consumer communications that rivals cannot yet replicate.
PMI reported that smoke-free products accounted for 43% of its first-quarter 2026 total net revenues, and the company says it estimates its smoke-free portfolio was used by more than 43 million consumers globally as of end-2025. The MRTP authorisation for ZYN is likely to be cited in future regulatory submissions in other markets as evidence of a rigorous scientific assessment, though international regulators operate under distinct frameworks and are not bound by FDA conclusions.
Public health advocates have historically contested MRTP applications on the grounds that reduced-risk labelling may attract non-smokers, particularly younger adults. The FDA's population-health calculus is intended to account for that risk, but the debate around oral nicotine products and initiation rates among non-smokers is ongoing and will shape how the ZYN authorisation is received outside the company's investor base.